Meeting
2017 Gastrointestinal Cancers Symposium
Phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) ± gemcitabine (Gem) in solid tumors: Interim results from the pancreatic cancer (PC) cohorts.
Authors
Zev A. Wainberg
University of California, Los Angeles, Medical Center, Los Angeles, CA
Zev A. Wainberg , Howard S. Hochster , Ben George , Martin Gutierrez , Mark Emery Johns , E. Gabriela Chiorean , Eunice Lee Kwak , Aparna Kalyan , Victoria Manax , Moncy Ye , Tianlei Chen , Nataliya Trunova , Peter J. O'Dwyer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02309177
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 412)
DOI
10.1200/JCO.2017.35.4_suppl.412
Abstract #
412
Poster Bd #
J18
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.
First Author: Yan-Shen Shan
Poster
2022 ASCO Annual Meeting
Sequential first-line treatment with gemcitabine plus nab-paclitaxel (GA) followed by FOLFIRINOX (FFX) versus FFX alone in patients with metastatic pancreatic cancer (PC): GABRINOX-2 randomized phase 2 trial.
First Author: Fabienne Portales
Poster
2021 Gastrointestinal Cancers Symposium
AGIG chemo-immunotherapy in patients with advanced pancreatic cancer: A single-arm, single-center, phase II study.
First Author: Wangshu Dai
Poster
2018 Gastrointestinal Cancers Symposium
Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer.
First Author: Suguru Yamada